Target intelligence / Profile preview

Vacuolar-type H+-ATPase V0 domain (V0 domain)

Target
V0 domain
Molecular classification
Enzyme, Transporter, Proton pump, Rotary motor
01

Overview

The Vacuolar-type H+-ATPase (V-ATPase) V0 domain is the membrane-embedded sector of a multi-subunit enzyme that functions as an ATP-driven proton pump [3, 10]. It is responsible for the translocation of protons across biological membranes, a process essential for acidifying intracellular organelles such as lysosomes, endosomes, and the Golgi apparatus [1, 11]. This acidification is critical for various cellular processes, including protein degradation, receptor recycling, and nutrient sensing via the mTORC1 pathway [4, 11]. In specialized cells like osteoclasts, the V0 domain is targeted to the plasma membrane to facilitate bone resorption, while in cancer cells, its overexpression promotes an acidic microenvironment that favors invasion, metastasis, and drug resistance [8, 16]. The V0 domain also plays a non-canonical role in membrane fusion by interacting with SNARE proteins [5]. Pharmacological inhibitors, such as bafilomycin A1 and archazolid, target the V0 c-subunit ring to block proton transport, making the V0 domain a significant therapeutic target for osteoporosis, viral infections, and oncology [8, 13]. However, the ubiquitous nature of V-ATPases presents challenges for achieving tissue-specific inhibition and avoiding systemic toxicity [9].

Other names
V0 sectorV-ATPase V0 domainVacuolar proton-translocating ATPase V0 domainV-type H+-ATPase V0 membrane domain
02

Mechanism of action

Inhibition of proton translocation by binding to the proteolipid c-subunit ring of the V0 domain, which prevents the rotation of the V0 sector relative to the V1 sector and disrupts the ATP-driven proton pumping mechanism [10, 13, 15].

03

Biological functions

Proton translocationOrganelle acidificationMembrane fusionpH sensingNutrient sensing
04

Disease associations

CancerOsteoporosisInfectionNeurodegenerative diseaseRenal tubular acidosis
05

Safety considerations

Systemic toxicity due to ubiquitous expressionLysosomal dysfunctionImpaired protein degradationPotential for renal and bone side effectsNarrow therapeutic window
06

Interacting drugs

Bafilomycin A1

7 more in the full profile.

07

Biomarkers

ATP6V0A3 (a3 isoform) expressionATP6V0A4 (a4 isoform) expressionLysosomal pHBone resorption markers (CTx, NTx)

Beyond the preview

Go deeper on Vacuolar-type H+-ATPase V0 domain (V0 domain).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vacuolar-type H+-ATPase V0 domain (V0 domain).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call